Successful development and use of biomarkers will improve the productivity of oncology drug development. Recognition of the importance of biomarkers for speeding drug development is reflected in the precise definitions and concepts proposed by an NIH Working Group to standardize terminology and promote a more coherent and systematic approach to the development and use of biomarkers. Potential clinical biomarkers of drug efficacy are often identified through pre-clinical studies or basic research. Identification of potential biomarkers for use in oncology is moving rapidly forward through continuing advances in clinical imaging technologies, especially molecular and functional imaging. Other rapid advances are a product of the growing availability of new scientific reagents for established technologies and of high-throughput genomic and proteomic technologies that can generate hundreds of potential biomarkers for further evaluation. In certain cases, conventional clinical diagnostic techniques or assays can be adapted for use in pre-clinical models to evaluate their ability to serve as biomarkers for predicting clinical responses to new drug candidates. Evaluation (pre-clinical and clinical) of a potential biomarker is often the longest stage of biomarker development, and standards for evaluation or validation depend on the intended use and stage of clinical development. Biomarkers verified for use in preclinical studies can be used to help select appropriate animal models and lead compounds. Biomarkers verified for use in clinical trials can confirm a drug's pharmacological or biological mechanism of action, guide protocol design, aid patient and dose selection, and help to minimize safety risks. Oncology drug development can be optimized by using a tiered set of clinical biomarkers that predict compound efficacy and safety with increasing confidence at each rise in tier thereby aiding corporate decision-making about advancing compounds. In oncology, a special class of extensively evaluated biomarkers of efficacy (surrogate endpoints) that generally correlate with desired clinical outcomes can be used as a basis for corporate decisions as well as for gaining accelerated provisional regulatory approval of a drug.
Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J.M., Herbst, R., LoRusso, P., Rischin, D., Sauleda, S., Gee, J., Nicholson, R.I., and Baselga, J. (2002). Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol20(1), 110—24.
2.
Allen, L.F., Lenehan, P.F., Eiseman, I.A., Elliott, W.L., and Fry, D.W. (2002). Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol29 (3 Suppl 11), 11— 21.
3.
Ardekani, A.M., Petricoin, E.F., and Hackett, J.L. (2003). Molecular diagnostics: an FDA perspective. Expert Rev Mol Diagn32(2), 129—40.
4.
Arteaga, C.L. (2003). Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res5(2), 96—100.
5.
Baak, J.P.A. (2002). The framework of pathology: Good Laboratory Practice by quantitative and molecular methods. J Pathol198, 277—83.
6.
Barker, P.E. (2003). Cancer biomarker validation: standards and process. Roles for the National Institute of Standards and Technology (NIST). Ann NY Acad Sci983, 142—50.
7.
Bernard, P.S., and Wittwer, C.T. (2002). Real-time PCR technology for cancer diagnostics . Clin Chem48(8), 1178—85.
8.
Beshara, N., Fung, M.F.K., and Faught, W. (2002). The role of topotecan as a second-line therapy in patients with recurrent ovarian cancer. Eur J Gynaecol Oncol23, 287—90.
9.
Betensky, R.A., Louis, D.N., and Cairncross, J.G. (2002). Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol20(10), 2495—9.
10.
Biomarkers Defininitions Working Group (2001 ). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharma col Ther69, 89—95.
11.
Blasberg, R. (2003). Molecular imaging and cancer. Mol Cancer Ther2, 333—43.
12.
Brodie, A. (2003). Aromatose inhibitor development and hormone therapy: a perspective. Semin Oncol30, 12—22.
13.
Bruzzi, P. (2002). Objective response to treatment as a potential surrogate marker of survival in breast cancer. Ann NY Acad Sci963, 144—7.
14.
Butte, A. (2002). The use and analysis of microarray data. Nature Rev Drug Disc1(12), 951—60.
15.
Camp, R.L., Chung, G.G., and Rimm, D.L. (2002). Automated subcellular localization and quantification of protein expression in tissue microarrays. Nature Med8(11), 1323—7.
16.
Capdeville, R., Buchdunger, E., Zimmermann, J., and Matter, A. (2002). Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug. Nature Rev Drug Discov1(7), 493—502.
17.
Chaurand, P., Schwartz, S.A., and Caprioli, R. (2002). Imaging mass spectrometry: a new tool to investigate the spatial organization of peptides and proteins in mammalian tissue sections . Curr Opin Chem Biol6(5), 676—81.
18.
Choyke, P.E., Dwyer, A.J., and Knopp, M.V. (2003). Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Res Imaging17, 509—20.
19.
Colburn, W.A. (2003). Biomarkers in drug discovery and development: From target identification through drug marketing. J Clin Pharmacol43(4), 329— 41.
20.
Dancey, J., and Sausville, E.A. (2003). Issues and progress with protein kinase inhibitors for cancer treatment. Nature Rev Drug Disc2, 296—313.
21.
De Gruttola, V.G., Clax, P., DeMets, D.L., Downing, G.J., Ellenberg, S.S., Friedman, L., Gail, M.H., Prentice, R., Wittes, J., and Zeger, S.L. (2001). Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop . Control Clin Trials22(5), 485—502.
22.
Deptala, A., Bedner, E., and Darzynkiewicz, Z. (2001). Unique analytical capabilities of laser scanning cytometry that complement flow cytometry. Folia Histochem Cytobiol39, 87—9.
23.
DePrimo, S.E., Wong, L.M., Khatry, D.B., Nicholas, S.L., Manning, W.C., Smolich, B.D., O'Farrell, A.M., and Cherrington, J.M. (2003). Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. BMCCancer3, 3.
24.
DiMasi, J.A. (2002). The value of improving the productivity of the drug development process. Pharmacoeconomics20 (Suppl. 3), 1—10.
25.
DiMasi, J.A., Hansen, R.W., and Grabowski, H.G. (2003). The price of innovation: new estimates of drug development costs. J Health Econ22(2), 151—85.
26.
Duffy, M.J. (2001). Clinical uses of tumor markers: a critical review . Crit Rev Clin Lab Sci38(3), 225—62.
27.
Early Detection Research Network (2002). Translational research to identify early cancer and cancer risk, second report . 〈http://www.3.cancer.gov/prevention/cbrg/edrn/publications.html 〉.
28.
Eckelman, W.C. (2003). The use of PET and knockout mice in the drug discovery process. Drug Discov Today8(9), 404—10.
29.
Fauntleroy, M. (2001). Submission of images to the Center for Biologics Evaluation and Research in support of license applications for therapeutic agents. J Clin Pharmacol41 (Suppl. S), 119S—21S.
30.
Frank, R., and Hargreaves, R. (2003). Clinical biomarkers in drug discovery and development . Nature Rev Drug Discov2(7), 566—80.
31.
Haedicke, W., Popper, H.H., Buck, C.R., and Zatloukal, K. (2003). Automated evaluation and normalization of immunohistochemistry on tissue microarrays with a DNA microarray scanner. Biotechniques35, 164—8.
32.
Han, M., Gao, X., Su, J.Z., and Nie, S. (2001). Quantum-dot-tagged microbeads for multiplexed optical coding of biomolecules. Nature Biotechnol19, 631—5.
33.
Hariharan, R. (2003). The analysis of microarray data. Pharmacogenomics4, 477—97.
34.
Hirschfeld, S., and Pazdur, R. (2002). Oncology drug development: United States Food and Drug Administration perspective. Crit Rev Oncol Hematol42(2), 137—43.
35.
Howell, K., Hopkins, N., and Mcloughlin, P. (2002). Combined confocal microscopy and stereology: a highly efficient and unbiased approach to quantitative structural measurement in tissues. Exp Physiol87(6), 747— 56.
36.
Howells, S.L., Maxwell, R.J., and Griffiths, J.R. (1992). Classification of tumor 1 H NMR spectra by pattern recognition. NMR Biomed5, 59—64.
37.
Howells, S.L., Maxwell, R.J., Howe, F.A., Peet, A.C., Stubbs, M., Rodrigues, L.M., Robinson, S.P., Baluch, S., and Griffiths, J.R. (1993). Pattern recognition of 31P magnetic resonance spectroscopy tumour spectra obtained in vivo. NMR Biomed6, 237—41.
38.
Huang, E., Ishida, S., Pittman, J., Dressman, H., Bild, A., Kloos, M., D'Amico, M., Pestell, R.G., West, M., and Nevins, J.R. (2003). Gene expression phenotypic models that predict the activity of oncogenic pathways. Nature Genet34, 226—30.
39.
Hutchinson, O.C., Collingridge, D.R., Barthel, H., Price, P.M., and Aboagye, E.O. (2003). Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography. J Curr Pharm Des9, 917—29.
40.
Hutchinson, O.C., Collingridge, D.R., Barthel, H., Price, P.M., and Aboagye, E.O. (2003). Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography. J Curr Pharm Des9, 931—44.
41.
Jackson, J.K., Gleave, M.E., Yago, V., Beraldi, E., Hunter, W.L., and Burt, H.M. (2000). The suppression of human prostate tumor growth in mice by the injection of a slow-release polymeric paste formulation of paclitaxel. Cancer Res60(15), 4146—51.
42.
Johnson, J.R., Williams, G., and Pazdur, R. (2003). End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol21, 1404—11.
43.
Jubb, A.M., Landon, T.H., Burwick, J., Pham, T.Q., Frantz, G.D., Cairns, B., Quirke, P., Peale, F.V., and Hillan, K.J. (2003). Quantitative analysis of colorectal tissue microarrays by immunofluorescence and in situ hybridization. J Pathol200(5), 577—88.
44.
Kamentsky, L.A., Burger, D.E., Gershman, R.J., Kamentsky, L.D., and Luther, E. (1997). Slide-based laser scanning cytometry. Acta Cytol41, 123— 43.
45.
Kavanaugh, C.J., Desai, K.V., Calvo, A., Brown, P.H., Couldrey, C., Lubet, R., and Green, J.E. (2002). Preclinical applications of transgenic mouse mammary cancer models. Transgenic Res11, 617—33.
46.
Kellar, K.L., and Iannone, M.A. (2002). Multiplexed microsphere-based flow cytometric assays. Expl Hematol30(11), 1227—37.
47.
Kennedy, T. (1997). Managing the drug discovery/development interface . Drug Discov Today2(10), 436—44.
48.
Keyes, K.A., Mann, L., Cox, K., Treadway, P., Iversen, P., Chen, Y.F., and Teicher, B.A. (2003). Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. Cancer Chemother Pharmacol51(4), 321—7.
49.
Korn, E.L., Arbuck, S.G., Pluda, J.M., Simon, R., Kaplan, R.S., and Christian, M.C. (2001). Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol19(1), 265—72.
50.
Lee, K.E., Sha, N., Dougherty, E.R., Vannucci, M., and Mallick, B.K. (2003). Gene selection: a Bayesian variable selection approach. Bioinformatics19, 90—7.
51.
Lesko, L.J., and Atkinson, A.J. (2001). Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies . Annu Rev Pharmacol Toxicol41, 347—66.
52.
Lim, Y.T., Kim, S., Nakayama, A., Stott, N.E., Bawendi, M.G., and Grangioni, J.V. (2003). Selection of quantum dot wavelengths for biomedical assays and imaging. Mol Imaging2, 50—64.
53.
Liotta, L.A., Espina, V., Mehta, A.I., Calvert, V., Rosenblatt, K., Geho, D., Munson, P.J., Young, L., Wulfkuhle, J., and Petricoin E.F. (2003). Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell3(4), 317—25.
54.
Lopez, A.M., Pegram, M.D., Slamon, D.J., and Landaw, E.M. (1999). A model-based approach for assessing in vivo combination therapy interactions. Proc Natl Acad Sci96, 13023—8.
55.
Ma, P.C., Blaszkowsky, L., Bharti, A., Ladanyi, A., Kraeft, S.K., Bruno, A., Skarin A.T., Chen, L.B., and Salgia, R. (2003). Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res23(1A), 49—62.
56.
MacGregor, P.F., and Squire, J.A. (2002). Application of microarrays to the analysis of gene expression in cancer. Clin Chem48(8), 1170—7.
57.
Malik, S.N., Siu, L.L., Rowinsky, E.K., deGraffenried, L., Hammond, L.A., Rizzo, J., Bacus, S., Brattain, M.G., Kreisberg, J.I., and Hidalgo, M. (2003). Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res9, 2478—86.
58.
Mancuso, P., Calleri, A., Cassi, C., Gobbi, A., Capillo, M., Pruneri, G., Martinelli, G., and Bertolini, F. (2003). Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol522, 83—97.
59.
Mandell, J.W. (2003). Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol163, 1687—98.
60.
Mannix, D.G. (2000). Irinotecan—a case study for the transition from accelerated approval to traditional approval. Drug Inform J34, 737—40.
61.
Massoud, T.F., and Gamghir, S.S. (2003). Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev17, 545—80.
62.
Mauro, M.J., O'Dwyer, M., Heinrich, M.C., and Druker, B.J. (2002). STI571: A paradigm of new agents for cancer therapeutics . J Clin Oncol20, 325—34.
63.
McCaffrey, A., Kay, M.A., and Contag, C.H. (2003). Advancing molecular therapies through in vivo bioluminescent imaging. Mol Imaging2, 75— 86.
64.
McDonald, D.M., and Choyke, P.L. (2003). Imaging of angiogenesis: from microscope to clinic . Nature Med9, 713—25.
65.
McIntosh, M.W., and Urban, N. (2003). A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics4, 27—40.
66.
Mendelsohn, J., and Baselga, J. (2003). Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol21(14), 2787—99.
67.
Mengel, M., von Wasielewski, R., Wiese, B., Rudiger, T., Muller-Hermelink, H., and Kreipe, H. (2002). Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol198, 292—9.
68.
Nicholson, J.K., Connelly, J., Lindon, J.C., and Holmes, E. (2002). Metabonomics: a platform for studying drug toxicity and gene function. Nature Rev Drug Discov1(2), 153—61.
69.
Nicholson, J.K., and Wilson, I.D. (2003). Opinion: understanding `global' systems biology: metabonomics and the continuum of metabolism. Nature Rev Drug Discov2(8), 668—76.
70.
Nielsen, U.B., Cardon, M.H., Sinskey, A.J., MacBeath, G., and Sorger, P.K. (2003). Profiling receptor tyrosine kinase activation by using Ab arrays. Proc Natl Acad Sci USA100, 9330—5.
71.
Nishizuka, S., Chen, S., Gwadry, F.G., Alexander, J., Major, S.M., Scherf, U., Reinhold, W.C., Waltham, M., Charbonneau, L., Young, L., Bussey, K.J., Kim, S., Lababidi, S., Lee, J.K., Pittaluga, S., Scudiero, D.A., Sausville, E.A., Munson, P.J., Petricoin, E.F., Liotta, L.A., Hewitt, S.M., Raffeld, M., and Weinstein, J.N. (2003). Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic and tissue array profiling. Cancer Res63, 5243—50.
72.
Ochs, M.F., and Godwin, A.K. (2003). Microarrays in cancer: research and application . Biotechniques34, S4—S15.
73.
Parekattil, S.J., Fisher, H.A., and Kogan, B.A. (2003). Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractatn protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer. J Urol169, 917—20.
74.
Parton, M., Krajewski, S., Smith, I., Krajewska, M., Archer, C., Naito, M., Ahern, R., Reed, J., and Dowsett, M. (2002). Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin Cancer Res8(7), 2100—8.
75.
Paweletz, C.P., Charboneau, L., Bichsel, V.E., Simone, N.L., Chen, T., Gillespie, J.W., Emmert-Buck, M.R., Roth, M.J., Petricoin, E.F., and Liotta, L.A. (2001). Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene20, 1981—9.
76.
Pepe, M.S., Etzioni, R., Feng, Z.D., Potter, J.D., Thompson, M.L., Thornquist, M., Winget, M., and Yasui, Y. (2001). Phases of biomarker development for early detection of cancer. J Natl Cancer Inst93(14), 1054—61.
77.
Petricoin, E.F., Hackett, J.L., Lesko, L.J., Puri, R.K., Gutman, S.I., Chumakov, K., Woodcock, J., Feigal, D.W., Zoon, K.C., and Sistare, F.D. (2002). Medical applications of microarray technologies: a regulatory science perspective. Nature Genet32(Suppl. S), 474—9.
78.
Petricoin, E.F., Zoon, K.C., Kohn, E.C., Barrett, J.C., and Liotta, L.A. (2002). Clinical proteomics: Translating benchside promise into bedside reality. Nature Rev Drug Discov1(9), 683—95.
79.
Ringner, M., and Peterson, C. (2003). Microarray-based cancer diagnosis with artificial neural networks. Biotechniques34, S30—5.
80.
Rolan, P., Atkinson, A.J., and Lesko, L.J. (2003). Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin Pharmacol Ther73, 284—91.
81.
Ross, B.D., Moffat, B.A., Lawrence, T.S., Mukherji, S.K., Gebarski, S.S., Quint, D.J., Johnson, T.D., Junck, L., Robertson, P.L., Muraszko, K.M., Dong, Q., Meyer, C.R., Bland, P.H., McConville, P., Geng, H., Rehemtulla, A., and Chenevert, T.L. (2003). Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther2, 581—7.
82.
Rudin, M., and Weissleder, R. (2003). Molecular imaging in drug discovery and development . Nature Rev Drug Discov2, 123—31.
83.
Sabri, S., Richelme, F., Pierres, A., Benoliel, A., and Bongrand, P. (1997). Interest of image processing in cell biology and immunology. J Immunol Meth208, 1—27.
84.
Sauter, G., Simor, R., and Hillan, K. (2003). Tissue microarrays in drug discovery. Nature Drug Disc2, 962—72.
85.
Sidransky, D. (2002). Emerging molecular markers of cancer. Nature Rev Cancer2, 210—9.
86.
Sindhi, R., Allaert, J., Gladding, D., Haaland, P., Koppelman, B., Dunne, J., and Sehgal, S. (2003). Modeling individual variation in biomarker response to combination immunosuppression with stimulated lymphocyte responses—potential clinical implications. J Immunol Meth272(1—2), 257—72.
87.
Shockcor, J.P., and Holmes, E. (2002). Metabonomic applications in toxicity screening and disease diagnosis. Curr Top Med Chem2, 35—51.
88.
Srinivas, P.R., Verma, M., Zhao, Y.M., and Srivastava, S. (2002). Proteomics for cancer biomarker discovery. Clin Chem48(8), 1160—9.
89.
Staal, F.J.T., van der Burg, M., Wessels, L.F.A., Barendregt, B.H., Baert, M.R.M., van den Burg, C.M.M., Van Huffel, C., Langerak, A.W., van der Velden, V.H.J., Reinders, M.J.T., and van Dongen, J.J.M. (2003). DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers. Leukemia17(7), 1324—32.
90.
Stadler, W. (2002). New trial designs to assess antitumor and antiproliferative agents in prostate cancer. Invest New Drugs20, 201—8.
91.
Sturgeon, C. (2002). Practice guidelines for tumor marker use in the clinic. Clin Chem48(8), 1151—9.
Tarnok, A., and Gerstner, A.O.H. (2003). Clinical applications of laser scanning cytometry. Cytometry50, 133—43.
94.
Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A.T., Christian, M.C., and Gwyther, S.G. (2000). New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst92, 205—16.
95.
Ugrinska, A., Bombardieri, E., Stokkel, M.P.M., Crippa, F., and Pauwels, E.K.J. (2002). Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer. Q J Nucl Med46(2), 88— 104.
96.
van der Velden, V.H.J., Hochhaus, A., Cazzaniga, G., Szczepanski, T., Gabert, J., and van Dongen, J.J.M. (2003). Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia17(6), 1013—34.
97.
Veltri, R.W., Miller, M.C., and An, G. (2001). Standardization, analytical validation, and quality control of intermediate endpoint biomarkers. Urology57(4A Suppl. S), 164—70.
98.
Welsh, J.B., Sapinoso, L.M., Kern, S.G., Brown, D.A., Liu, T., Bauskin, A.R., Ward, R.L., Hawkins, N.J., Quinn, D.I., Russell, P.J., Sutherland, R.L., Breit, S.N., Moskaluk, C.A., Frierson, H.F., and Hampton, G.M. (2003). Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA100, 3410—5.
99.
Wulfkuhle, J.D., Liotta, L.A., and Petricoin, E.F. (2003). Proteomic applications for the early detection of cancer. Nature Rev Cancer3(4), 267—75.
100.
Yamori, T. (2003). Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother Pharmacol52 (Suppl. 1), S74—9.
101.
Zehentner, B.K., Dillon, D.C., Jiang, Y.Q., Xu, J.C., Bennington, A., Molesh, D.A., Zhang, X.Q., Reed, S.G., Persing, D.H., and Houghton, R.L. (2002). Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes. Clin Chem48(8), 1225—31.
